What's new

Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Withdrawn

Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Withdrawn

Mar 12, 2025 - 17:04
 0
Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: sutimlimab Treatment of autoimmune haemolytic anaemia, 11/02...

Next Article

Orphan designation: Adeno-associated viral vector serotype rh10 containing the h...

Related Posts

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 10, 2025  0

Herbal medicinal product: Anisi aetheroleumArray, C: ongoing call for scientific data

Herbal medicinal product: Anisi aetheroleumArray, C: on...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Exforge, amlodipine,valsartan, Date of authorisation: 16/01/2007, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0